| Literature DB >> 35396264 |
Nicky McCreesh1, Aaron S Karat2,3, Indira Govender2,4, Kathy Baisley2, Karin Diaconu3, Tom A Yates5, Rein Mgj Houben2, Karina Kielmann3, Alison D Grant2,4,6, Richard White2.
Abstract
BACKGROUND: There is a high risk of Mycobacterium tuberculosis (Mtb) transmission in healthcare facilities in high burden settings. WHO guidelines on tuberculosis (TB) infection prevention and control (IPC) recommend a range of measures to reduce transmission in healthcare settings. These were evaluated primarily based on evidence for their effects on transmission to healthcare workers in hospitals. To estimate the overall impact of IPC interventions, it is necessary to also consider their impact on community-wide TB incidence and mortality.Entities:
Keywords: HIV; epidemiology; mathematical modelling; public health; tuberculosis
Mesh:
Year: 2022 PMID: 35396264 PMCID: PMC8995945 DOI: 10.1136/bmjgh-2021-007136
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Simulated TB states. Blue and green boxes show the natural history for HIV−/HIV+ART+ and HIV+ART− individuals respectively. Grey arrows indicate tuberculosis mortality. Red outlines indicate infectious states. ART, antiretroviral therapy; TB, tuberculosis.
Simulated parameter values for mean monthly contact hours occurring between household members, in clinics, and in other congregate settings, by simulated population group, for people without TB
| Sex | Age group (years) | HIV/ART status | Estimated mean contact hours per month | ||
| Household members | Clinics | Other congregate settings | |||
| Male | 15–29 | HIV−/HIV+ not on ART | 3175 | 50 | 2315 |
| HIV+ on ART | 3175 | 99 | 1939 | ||
| 30–49 | HIV−/HIV+ not on ART | 3175 | 50 | 1636 | |
| HIV+ on ART | 3175 | 99 | 1260 | ||
| 50–79 | HIV−/HIV+ not on ART | 3175 | 50 | 1567 | |
| HIV+ on ART | 3175 | 99 | 1191 | ||
| Female | 15–29 | HIV−/HIV+ not on ART | 3175 | 91 | 2394 |
| HIV+ on ART | 3175 | 138 | 2017 | ||
| 30–49 | HIV−/HIV+ not on ART | 3175 | 91 | 1714 | |
| HIV+ on ART | 3175 | 138 | 1338 | ||
| 50–79 | HIV−/HIV+ not on ART | 3175 | 91 | 1646 | |
| HIV+ on ART | 3175 | 138 | 1269 | ||
ART, antiretroviral therapy; TB, tuberculosis.
Figure 2Model fit to estimated (A) TB incidence, (B) mortality and (C) treatment coverage. *Treatment coverage is calculated as the ratio of the number of people starting treatment in a year to the estimated number of people developing TB in the same year. Lines over time show model output. Points and error bars show the fitting targets, based on empirical data. The ribbon in plot (A) shows the empirical estimates over time. Empirical estimates over time were not available for KwaZulu-Natal for the other fitting outputs shown here. TB, tuberculosis.
Figure 3The estimated proportion of contact time and infections that occurs in clinics, and the proportion of disease that resulted from transmission in clinics in the study population in 2019, overall, in HIV-positive people, HIV-negative people and for MDR-TB. For contact time, the central bar shows the proportion for the best estimate scenario, and the range of the bars shows the proportions in the contact time in clinics sensitivity analysis. For infections and disease, the central horizontal bar shows the best estimate, and the range of the bars shows the most extreme results from the sensitivity analyses. MDR, multidrug resistant; TB, tuberculosis.
Figure 4The estimated reduction in TB cases and deaths in the study population in 2021–2030 resulting from the proposed infection control interventions. The central horizontal bar shows the best estimate, and the range of the bars shows the most extreme results from the sensitivity analyses. CCMDD, Central Chronic Medicine Dispensing and Distribution; TB, tuberculosis; UVGI, ultraviolet germicidal irradiation.